Combined ablation for paroxysmal atrial fibrillation and drug-refractory hypertrophic obstructive cardiomyopathy: a case report.
4D-flow MRI
Alcohol septal ablation
Atrial fibrillation
Case report
Hypertrophic obstructive cardiomyopathy
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
19
01
2020
revised:
25
03
2020
accepted:
18
12
2020
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Hypertrophic obstructive cardiomyopathy (HOCM) is sometimes concomitant with atrial fibrillation (AF) and exacerbates heart failure symptoms. Although optimal medication for the reduction of left ventricular outflow tract (LVOT) obstruction and the maintenance of sinus rhythm should be considered, it is difficult to control the symptoms permanently. A 45-year-old man, diagnosed with HOCM, presented with progressive dyspnoea on exertion, which significantly deteriorated during episodes of paroxysmal AF, despite optimal medical therapy. On echocardiography, we found LVOT obstruction with a peak pressure gradient of 98 mmHg, concomitant with redundant mitral valve leaflets, which caused significant systolic anterior motion (SAM). Since he declined open surgery, we selected a combination of catheter interventions, AF ablation, and alcohol septal ablation (ASA). After the AF ablation, the occurrence of AF significantly decreased, and there was no recurrence after the ASA. By 6 months, the plasma N-terminal pro-B-type natriuretic peptide level had decreased from 1022 to 124 pg/mL, the peak pressure gradient of LVOT decreased from 98 to 12 mmHg, and the left atrium volume decreased from 203 to 178.4 mL. The improvement in the SAM was visualized on echocardiography and was haemodynamically corroborated by the four-dimensional (4D)-flow cardiac magnetic resonance (CMR). The treatment of drug-refractory HOCM concomitant with paroxysmal AF needs both septal reduction and the maintenance of sinus rhythm, which can be accomplished through transcatheter interventions. Moreover, the detailed intra-ventricular haemodynamic assessment in HOCM patients can be explored using the 4D-flow CMR.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertrophic obstructive cardiomyopathy (HOCM) is sometimes concomitant with atrial fibrillation (AF) and exacerbates heart failure symptoms. Although optimal medication for the reduction of left ventricular outflow tract (LVOT) obstruction and the maintenance of sinus rhythm should be considered, it is difficult to control the symptoms permanently.
CASE SUMMARY
METHODS
A 45-year-old man, diagnosed with HOCM, presented with progressive dyspnoea on exertion, which significantly deteriorated during episodes of paroxysmal AF, despite optimal medical therapy. On echocardiography, we found LVOT obstruction with a peak pressure gradient of 98 mmHg, concomitant with redundant mitral valve leaflets, which caused significant systolic anterior motion (SAM). Since he declined open surgery, we selected a combination of catheter interventions, AF ablation, and alcohol septal ablation (ASA). After the AF ablation, the occurrence of AF significantly decreased, and there was no recurrence after the ASA. By 6 months, the plasma N-terminal pro-B-type natriuretic peptide level had decreased from 1022 to 124 pg/mL, the peak pressure gradient of LVOT decreased from 98 to 12 mmHg, and the left atrium volume decreased from 203 to 178.4 mL. The improvement in the SAM was visualized on echocardiography and was haemodynamically corroborated by the four-dimensional (4D)-flow cardiac magnetic resonance (CMR).
DISCUSSION
CONCLUSIONS
The treatment of drug-refractory HOCM concomitant with paroxysmal AF needs both septal reduction and the maintenance of sinus rhythm, which can be accomplished through transcatheter interventions. Moreover, the detailed intra-ventricular haemodynamic assessment in HOCM patients can be explored using the 4D-flow CMR.
Identifiants
pubmed: 33644658
doi: 10.1093/ehjcr/ytaa570
pii: ytaa570
pmc: PMC7898580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ytaa570Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Open Heart. 2018 May 10;5(1):e000786
pubmed: 29765615
Circulation. 2011 Dec 13;124(24):e783-831
pubmed: 22068434
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Gen Thorac Cardiovasc Surg. 2018 Jul;66(7):379-389
pubmed: 29616461
Eur J Heart Fail. 2016 Sep;18(9):1106-18
pubmed: 27109894
Eur Heart J Cardiovasc Imaging. 2018 Dec 1;19(12):1389
pubmed: 30202957
Heart. 2016 Oct 1;102(19):1533-43
pubmed: 27234160
Circulation. 2001 Nov 20;104(21):2517-24
pubmed: 11714644
Heart. 2014 Mar;100(6):465-72
pubmed: 24014282